angn - ANGN STOCK NEWS

Angion Biomedica Corp. (NASDAQ:ANGN) will host a virtual research and development day on September 20 at 10:00 AM EDT, focusing on its candidate ANG-3070, a selective tyrosine kinase receptor inhibitor for fibrotic diseases. Medical experts will discuss current treatment landscapes for kidney and lung fibrosis. The event includes presentations by Dr. Joseph V. Bonventre from Harvard Medical School and Dr. Gregory P. Downey from National Jewish Health, followed by a live Q&A. Angion is committed to advancing treatments for organ injuries and fibrosis, with ANG-3777 in Phase 3 trials for kidney transplantation.

Angion Biomedica Corp (NASDAQ:ANGN) announced its management will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 AM EDT and participate in a fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:45 AM EDT. Webcasts for both events will be accessible on Angion's investor website and archived for 30 days. Angion is focused on developing novel therapies for acute organ injuries and fibrotic diseases, including ANG-3777 and ANG-3070.

Angion Biomedica Corp (NASDAQ:ANGN) has announced a shift in timeline for the ANG-3777 Phase 3 trial data release to early Q4 2021, due to expedited data cleaning. The company is also optimistic about ANG-3070, which demonstrated favorable tolerability in Phase 1 trials and achieved drug exposure exceeding that in preclinical models. They plan to begin a Phase 2 trial for ANG-3070 in primary proteinuric kidney diseases this year. As of June 30, 2021, Angion held $117.3 million in cash, expected to sustain operations through Q4 2022.

Angion Biomedica Corp (NASDAQ:ANGN) announced positive results from its Phase 1 study of ANG-3070, a novel oral tyrosine kinase inhibitor for fibrotic diseases. The study showed that ANG-3070 was well-tolerated and achieved drug exposures exceeding those shown to be effective in animal models of kidney disease. Following this, the FDA accepted an IND application for a Phase 2 trial in patients with primary proteinuric kidney diseases, set to begin in late 2021. Additionally, the Company will host a Virtual Fibrosis R&D Day on September 20, 2021.

Angion Biomedica Corp. (NASDAQ:ANGN) announced that its Phase 2 ALI-201 trial of ANG-3777 for severe COVID-19 pneumonia failed to meet primary and secondary efficacy endpoints. Conducted in Brazil, the trial involved 120 patients and showed no significant survival benefit over standard care. The adverse events were slightly higher in the treatment group, yet no new safety signals were detected. Angion will not pursue this COVID-19 program further but plans to advance ANG-3777 in acute lung injury populations, with data from other trials expected by the end of 2021.

Angion Biomedica Corp (NASDAQ:ANGN) reported significant progress in 2021, completing enrollment in two Phase 2 trials for ANG-3777. They raised $117 million through an initial public offering and private placement. The company aims to share key data from their clinical pipeline this year, focusing on treatments for acute organ injuries. As of March 31, 2021, Angion had $130.5 million in cash, sufficient to fund operations into 2022. However, net losses increased to $36.7 million, up from $13.2 million in Q1 2020.

Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma have completed enrollment for the AKI-002-15 Phase 2 trial, assessing ANG-3777 in cardiac-surgery associated acute kidney injury (CSA-AKI). Topline results are anticipated in the second half of 2021. This trial aims to address the significant unmet need for therapies in CSA-AKI, which affects around one-third of cardiac surgery patients. The study involves multiple international sites and randomization of patients to receive ANG-3777 or placebo. The findings will guide the development of a Phase 3 registration trial, expected to commence in early 2022.

Angion Biomedica Corp. (NASDAQ:ANGN) has announced its fourth quarter and full year 2020 financial results and corporate update. The company raised $117 million from a recent IPO to support the development of lead candidate ANG-3777, aiming to address organ injuries and fibrotic diseases. In 2020, Angion completed enrollment for multiple clinical trials and signed a licensing deal with Vifor Pharma valued up to $1.9 billion for ANG-3777. However, net losses increased significantly to $80.1 million for the year, compared to $40.7 million in 2019.

Angion Biomedica Corp. (NASDAQ: ANGN) announced the completion of enrollment for its ALI-201 study, a Phase 2 trial evaluating ANG-3777 for acute lung injury in COVID-19 patients. The trial targets patients at high risk for acute respiratory distress syndrome (ARDS) and will measure survival rates free from mechanical ventilation or dialysis at 28 days. Preclinical data suggests ANG-3777 may aid in acute lung injury recovery. The company is also progressing in multiple trials for various indications, positioning ANG-3777 as a potential first-in-class treatment.